AIMS: To study the influence of patients' education and cardiovascular risk factors on the probability of statin treatment. METHODS: A prospective cohort study of participants in regional health surveys in Norway 2000-2002 with statin use recorded in the Norwegian Prescription Database 2004-2006 as outcome measure. Information on history of cardiovascular disease (CVD) and diabetes, lipid levels, blood pressure, use of cardiovascular drugs, body mass index, family history, smoking, physical activity, marital status and place of residence was obtained at baseline. A total of 20,212 men and women aged 40-41, 45-46 and 59-61 years who reported never use of statins were included. Educational level was retrieved from Statistics Norway. Adjusted relative risks (RR) were estimated by Poisson regression. RESULTS: Whereas 655 participants reported a history of CVD or diabetes, 19,557 reported no such history. In the non-CVD/diabetes group 1,620 persons (8%) became statin users and 222 persons (34%) in the CVD/diabetes group. RR of becoming a statin user for high vs. low education increased from 0.64 [95% confidence interval (CI) 0.55, 0.73] to 0.91 (95% CI 0.79, 1.05) after adjustment in the non-CVD/diabetes group and from 0.94 (95% CI 0.70, 1.26) to 1.35 (95% CI 1.00, 1.81) in the CVD/diabetes group. CONCLUSIONS: Patients with no history of CVD/diabetes were prescribed statins according to cardiovascular risk independent of education. There was a tendency to a higher probability of statin treatment among highly educated compared with people of lower educational level in the group with a history of CVD or diabetes, after adjustment for other CVD risk factors, particularly in women.
AIMS: To study the influence of patients' education and cardiovascular risk factors on the probability of statin treatment. METHODS: A prospective cohort study of participants in regional health surveys in Norway 2000-2002 with statin use recorded in the Norwegian Prescription Database 2004-2006 as outcome measure. Information on history of cardiovascular disease (CVD) and diabetes, lipid levels, blood pressure, use of cardiovascular drugs, body mass index, family history, smoking, physical activity, marital status and place of residence was obtained at baseline. A total of 20,212 men and women aged 40-41, 45-46 and 59-61 years who reported never use of statins were included. Educational level was retrieved from Statistics Norway. Adjusted relative risks (RR) were estimated by Poisson regression. RESULTS: Whereas 655 participants reported a history of CVD or diabetes, 19,557 reported no such history. In the non-CVD/diabetes group 1,620 persons (8%) became statin users and 222 persons (34%) in the CVD/diabetes group. RR of becoming a statin user for high vs. low education increased from 0.64 [95% confidence interval (CI) 0.55, 0.73] to 0.91 (95% CI 0.79, 1.05) after adjustment in the non-CVD/diabetes group and from 0.94 (95% CI 0.70, 1.26) to 1.35 (95% CI 1.00, 1.81) in the CVD/diabetes group. CONCLUSIONS:Patients with no history of CVD/diabetes were prescribed statins according to cardiovascular risk independent of education. There was a tendency to a higher probability of statin treatment among highly educated compared with people of lower educational level in the group with a history of CVD or diabetes, after adjustment for other CVD risk factors, particularly in women.
Authors: Ian Graham; Dan Atar; Knut Borch-Johnsen; Gudrun Boysen; Gunilla Burell; Renata Cifkova; Jean Dallongeville; Guy De Backer; Shah Ebrahim; Bjørn Gjelsvik; Christoph Herrmann-Lingen; Arno Hoes; Steve Humphries; Mike Knapton; Joep Perk; Silvia G Priori; Kalevi Pyorala; Zeljko Reiner; Luis Ruilope; Susana Sans-Menendez; Wilma Scholte Op Reimer; Peter Weissberg; David Wood; John Yarnell; Jose Luis Zamorano; Edmond Walma; Tony Fitzgerald; Marie Therese Cooney; Alexandra Dudina; Alex Vahanian; John Camm; Raffaele De Caterina; Veronica Dean; Kenneth Dickstein; Christian Funck-Brentano; Gerasimos Filippatos; Irene Hellemans; Steen Dalby Kristensen; Keith McGregor; Udo Sechtem; Sigmund Silber; Michal Tendera; Petr Widimsky; Jóse Luis Zamorano; Attila Altiner; Enzo Bonora; Paul N Durrington; Robert Fagard; Simona Giampaoli; Harry Hemingway; Jan Hakansson; Sverre Erik Kjeldsen; Mogens Lytken Larsen; Giuseppe Mancia; Athanasios J Manolis; Kristina Orth-Gomer; Terje Pedersen; Mike Rayner; Lars Ryden; Mario Sammut; Neil Schneiderman; Anton F Stalenhoef; Lale Tokgözoglu; Olov Wiklund; Antonis Zampelas Journal: Eur J Cardiovasc Prev Rehabil Date: 2007-09
Authors: Johan P Mackenbach; Vivian Bos; Otto Andersen; Mario Cardano; Giuseppe Costa; Seeromanie Harding; Alison Reid; Orjan Hemström; Tapani Valkonen; Anton E Kunst Journal: Int J Epidemiol Date: 2003-10 Impact factor: 7.196
Authors: Jeppe N Rasmussen; Gunnar H Gislason; Søren Rasmussen; Steen Z Abildstrom; Tina K Schramm; Lars Køber; Finn Diderichsen; Merete Osler; Christian Torp-Pedersen; Mette Madsen Journal: J Epidemiol Community Health Date: 2007-12 Impact factor: 3.710
Authors: Oyvind Naess; Anne Johanne Søgaard; Egil Arnesen; Anne Cathrine Beckstrøm; Espen Bjertness; Anders Engeland; Peter F Hjort; Jostein Holmen; Per Magnus; Inger Njølstad; Grethe S Tell; Lars Vatten; Stein Emil Vollset; Geir Aamodt Journal: Int J Epidemiol Date: 2007-11-04 Impact factor: 7.196
Authors: Linda Ernstsen; Bjørn Heine Strand; Sara Marie Nilsen; Geir Arild Espnes; Steinar Krokstad Journal: BMC Public Health Date: 2012-04-03 Impact factor: 3.295
Authors: Helle Wallach-Kildemoes; Finn Diderichsen; Allan Krasnik; Theis Lange; Morten Andersen Journal: BMC Public Health Date: 2012-08-04 Impact factor: 3.295
Authors: N R V Jones; C M Fischbacher; B Guthrie; G Leese; R S Lindsay; J A McKnight; D Pearson; S Philip; N Sattar; S H Wild Journal: Diabet Med Date: 2014-03-24 Impact factor: 4.359